Evaluation of CMV/EBV-CMI in Haploid HSCT

Recruiting now

Conditions studied: Hematopoietic Stem Cell Transplantation, Cytomegalovirus Infections, Epstein-Barr Virus Infections

In brief

The purpose of this prospective, open-label, Single Arm, single-center study is to evaluate the cytomegalovirus and Epstein-Barr virus specific immune reestablishment for patients with hemopathy undergoingin prophylaxis for cytomegalovirus in haploid hematopoietic stem cell transplantation(haplo-HSCT) .

Key facts

Study ID

NCT06554197

Run by

The First Affiliated Hospital of Soochow University

People needed

60

Starts

2024-08-13

Expected to finish

2026-07-31

Last updated by the study team

2024-08-15

Who can join

Age: 16 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• All patients were diagnosed with hemopathy.
• All patients should have the indication of Haploidentical hematopoietic stem cell transplant and receive the prophylaxis for cytomegalovirus.
• All patients should sign an informed consent document indicating that they understand the purpose of and procedures required for the study and be willing to participate in the study.

You may not qualify if…

• Patients with any conditions not suitable for the trial (investigators' decision).

Where it is running

• First Affiliated Hospital of Soochow University — Suzhou, Jiangsu, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.